TTM: Hypothermia after cardiac arrest does not offer benefits

Previous studies evaluated therapeutic hypothermia (32 ° C to 34 ° C for 12-24 hours) in patients who remain unconscious after resuscitation from cardiac arrest showing improvement in neurological recovery and survived. However, the ideal temperature is not set. 

This study enrolled 950 patients in 36 centers in Europe and Australia and randomized to hypothermia (33 ° C) or normothermia. The primary end point was death from all causes and the secondary a combination of death and neurological dysfunction at 180 days. The primary end point occurred in 50 % of the hypothermia group and 48 % in the normothermia group (HR 1.06 , 95% CI 0.89 to 1.28 , P = .51 ) . The results for the secondary end point were also similar.

Conclusion:

In unaware survivors of cardiac arrest outside hospital, hypothermia at a temperature of 33 ° C does not provide benefits versus normothermia.

Original article

3_niklas_nielsen_presentacion
Niklas Nielsen
2013-11-17

Original title: TTM trial: Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

More articles by this author

Mild hypothermia in pre-hospital phase after cardiac arrest

Hypothermia in the hospital phase at 32-34 ° C improves neurological outcome in patients resuscitated after ventricular fibrillation out of the hospital environment. In...

NIAMI: Nitroprusside infusion prior to primary angioplasty

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during...

CATIS: Immediate reduction in blood pressure demonstrated no benefit in acute stroke

It is shown that hypertension is associated with the occurrence of stroke but immediate treatment for an acute stroke itself is unclear. This study...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....